Aptose Biosciences (NASDAQ:APTO) Research Coverage Started at StockNews.com

StockNews.com initiated coverage on shares of Aptose Biosciences (NASDAQ:APTO) (TSE:APS) in a research report released on Saturday. The brokerage issued a sell rating on the biotechnology company’s stock.

A number of other brokerages have also issued reports on APTO. HC Wainwright raised their price objective on Aptose Biosciences from $2.00 to $6.00 and gave the stock a “buy” rating in a research note on Friday, March 28th. Alliance Global Partners raised shares of Aptose Biosciences to a “strong-buy” rating in a research report on Thursday, February 27th.

Aptose Biosciences Price Performance

The stock has a market capitalization of $3.66 million, a price-to-earnings ratio of -0.58 and a beta of 1.04. Aptose Biosciences has a 1-year low of $1.35 and a 1-year high of $50.10. The business has a 50-day moving average price of $4.41 and a two-hundred day moving average price of $7.37.

Hedge Funds Weigh In On Aptose Biosciences

An institutional investor recently bought a new position in Aptose Biosciences stock. Bleichroeder LP bought a new stake in shares of Aptose Biosciences Inc. (NASDAQ:APTO) (TSE:APS) in the fourth quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor bought 2,500,000 shares of the biotechnology company’s stock, valued at approximately $563,000. Bleichroeder LP owned about 4.15% of Aptose Biosciences at the end of the most recent reporting period. Institutional investors own 26.62% of the company’s stock.

Aptose Biosciences Company Profile

Aptose Biosciences Inc, a clinical-stage biotechnology company, discovers and develops personalized therapies addressing unmet medical needs in oncology in Canada. Its lead clinical program is APTO-253, which is a Phase I clinical trial for the treatment of patients with relapsed or refractory hematologic malignancies.